<DOC>
	<DOCNO>NCT00100984</DOCNO>
	<brief_summary>The main objective study compare safety efficacy enfuvirtide contain regimen nucleoside combination regimen . Resistance information also collect .</brief_summary>
	<brief_title>A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations See Efficacy These Treatments Patients Infected With HIV-1</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>CD4 cell count great 50 cells/mm^3 HIV1 RNA viral load great equal 5000 copies/mL Patients must HIV treatment experience Patients diagnosed HIV1 infection Female patient must able child must effective contraceptive Female patient pregnant Have take enfuvirtide and/or T1249 Have serious kidney problem Alcohol and/or drug abuse Have organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
</DOC>